FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology and represents an antibody which specifically binds to B7-H1, or an antigen-binding fragment thereof for use in treating a patient having a tumour which expresses B7-H1, wherein the patient is detected by detecting B7-H1 expression in one or more tumour cells, and where 25 % or more tumour cells contain membrane staining by B7-H1, where the use additionally involves using 0.1, 0.3, 1, 3, 10, or 15 mg/kg of antibody or its antigen-binding fragment.
EFFECT: invention allows extending the range of antibodies to B7-H1.
11 cl, 25 dwg, 19 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES TO B7-H1 FOR TREATING TUMOURS | 2014 |
|
RU2817281C2 |
| ANTIBODIES TO B7-H1 AND TO CTLA-4 FOR TREATING NON-SMALL-CELL LUNG CANCER | 2015 |
|
RU2702332C2 |
| ANTIBODIES TO B7-H1 AND CTLA-4 FOR THE TREATMENT OF NON-SMALL CELL LUNG CANCER | 2015 |
|
RU2806210C2 |
| COMBINATION OF PD-1 ANTAGONIST AND IDO1 INHIBITOR FOR TREATING ANCER | 2015 |
|
RU2744880C1 |
| TREATING LUNG CANCER BY COMBINATION OF ANTI-PD-1 AND OTHER ANTI-CANCER AGENTS | 2015 |
|
RU2695332C2 |
| COMBINATION OF ANTI-PD-L1 ANTIBODY AND DNA-PK INHIBITOR FOR TREATING MALIGNANT NEOPLASM | 2018 |
|
RU2765997C2 |
| COMBINATION | 2015 |
|
RU2744841C2 |
| METHODS OF TREATING CANCER USING PD-1 AND PD-L1 ANTAGONISTS IN COMBINATION WITH RADIATION THERAPY | 2015 |
|
RU2711408C2 |
| TREATING CANCER WITH COMBINATION OF PD-1 ANTAGONIST AND DINACICLIB | 2014 |
|
RU2705795C2 |
| PD-1/PD-L1 INHIBITORS FOR TREATING CANCER | 2016 |
|
RU2742312C1 |
